药品注册申请号:009175
申请类型:NDA (新药申请)
申请人:CASPER PHARMA LLC
申请人全名:CASPER PHARMA LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 FURADANTIN NITROFURANTOIN SUSPENSION;ORAL 25MG/5ML Yes No AB 1953/12/23 Approved Prior to Jan 1, 1982 Prescription
002 FURADANTIN NITROFURANTOIN SUSPENSION;ORAL 50MG/5ML Yes Yes None 2023/06/09 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/02/01 SUPPL-50(补充) Approval Labeling STANDARD
2023/06/09 SUPPL-49(补充) Approval Manufacturing (CMC) N/A
2020/12/23 SUPPL-48(补充) Approval Labeling STANDARD
2019/06/11 SUPPL-46(补充) Approval Labeling STANDARD
2016/07/11 SUPPL-44(补充) Approval Manufacturing (CMC) STANDARD
2014/11/03 SUPPL-43(补充) Approval Manufacturing (CMC) STANDARD
2013/11/04 SUPPL-36(补充) Approval Labeling STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
2010/10/27 SUPPL-38(补充) Approval Labeling STANDARD
2010/10/14 SUPPL-39(补充) Approval Labeling UNKNOWN
2009/02/06 SUPPL-37(补充) Approval Labeling STANDARD
2008/05/30 SUPPL-33(补充) Approval Labeling STANDARD
1999/08/25 SUPPL-26(补充) Approval Labeling STANDARD
1999/02/11 SUPPL-20(补充) Approval Labeling STANDARD
1998/12/03 SUPPL-25(补充) Approval Manufacturing (CMC) STANDARD
1998/04/07 SUPPL-22(补充) Approval Labeling STANDARD
1997/03/27 SUPPL-23(补充) Approval Labeling STANDARD
1996/10/15 SUPPL-24(补充) Approval Manufacturing (CMC) STANDARD
1993/08/09 SUPPL-21(补充) Approval Manufacturing (CMC) STANDARD
1993/05/18 SUPPL-15(补充) Approval Efficacy
1988/05/13 SUPPL-19(补充) Approval Labeling
1987/06/12 SUPPL-16(补充) Approval Labeling
1987/06/12 SUPPL-12(补充) Approval Labeling
1982/11/18 SUPPL-13(补充) Approval Labeling
1980/04/25 SUPPL-10(补充) Approval Labeling
1979/12/17 SUPPL-11(补充) Approval Labeling
1978/01/03 SUPPL-8(补充) Approval Manufacturing (CMC) STANDARD
1973/11/23 SUPPL-6(补充) Approval Supplement STANDARD
1953/12/23 ORIG-1(原始申请) Approval Type 3 - New Dosage Form STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:NITROFURANTOIN 剂型/给药途径:SUSPENSION;ORAL 规格:25MG/5ML 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
009175 001 NDA FURADANTIN NITROFURANTOIN SUSPENSION;ORAL 25MG/5ML Prescription Yes No AB Approved Prior to Jan 1, 1982 CASPER PHARMA LLC
201679 001 ANDA NITROFURANTOIN NITROFURANTOIN SUSPENSION;ORAL 25MG/5ML Prescription No No AB 2011/05/11 AMNEAL PHARMS
201355 001 ANDA NITROFURANTOIN NITROFURANTOIN SUSPENSION;ORAL 25MG/5ML Prescription No No AB 2013/08/14 NOSTRUM LABS INC
201693 001 ANDA NITROFURANTOIN NITROFURANTOIN SUSPENSION;ORAL 25MG/5ML Prescription No No AB 2014/09/08 NOVEL LABS INC
205180 001 ANDA NITROFURANTOIN NITROFURANTOIN SUSPENSION;ORAL 25MG/5ML Prescription No No AB 2016/05/03 ACTAVIS MID ATLANTIC
216385 001 ANDA NITROFURANTOIN NITROFURANTOIN SUSPENSION;ORAL 25MG/5ML Prescription No No AB 2023/04/14 NOVITIUM PHARMA
212607 001 ANDA NITROFURANTOIN NITROFURANTOIN SUSPENSION;ORAL 25MG/5ML Prescription No No AB 2023/05/11 AUROBINDO PHARMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database